TWN Info Service on Biosafety
25 September 2025
Third World Network
www.twn.my
Dear Friends and Colleagues
Burkino Faso Ends GM Mosquito Project
In August 2025, Burkina Faso announced a nationwide end to the activities of Target Malaria, the research consortium aiming to introduce gene drive mosquitoes for malaria control in sub-Saharan Africa. The decision effectively halts all experimentation with genetically modified (GM) mosquitoes in the country (Item 1).
The announcement follows Target Malaria’s second experimental release of 75,000 sterile male non-gene drive GM mosquitoes on August 11 in Houet province and Guiriko region as a potential malaria-control tool. This phase built on a smaller trial in July 2019 when 10,000 non-gene drive sterile male GM mosquitoes, imported as eggs from Italy, were released in Bana. Despite regulatory clearances, civil society groups strongly opposed the experiment.
With the government’s decision, Burkina Faso has formally shut down Target Malaria’s activities nationwide, reflecting growing scepticism over the safety, ethics, and necessity of GM mosquito experiments.
The Coalition for Monitoring Biotechnology Activities (CVAB) welcomed the move and issued a press release (Item 2). It said the decision demonstrated the authorities’ willingness to opt for solutions that respected public health, the environment, and citizens’ choices. In this regard, the Coalition pointed to the success of several countries in being certified malaria-free thanks to reliable and proven methods, which Burkina Faso could emulate.
With best wishes,
Third World Network
__________________________________________________________________________
Item 1
BURKINA FASO BANS GATES-BACKED GM MOSQUITO EXPERIMENTS, SAMPLES TO BE DESTROYED NATIONWIDE
Mayowa Durosinmi
West Africa Weekly
https://westafricaweekly.com/burkina-faso-bans-gates-backed-gm-mosquito-experiments-samples-to-be-destroyed-nationwide/
23 August 2025
Burkina Faso has announced a nationwide end to the activities of Target Malaria, the research consortium funded by the Bill & Melinda Gates Foundation and Open Philanthropy. The decision effectively halts all experimentation with genetically modified (GM) mosquitoes in the country.
In a statement released on Friday, August 22, the Minister of Higher Education, Research and Innovation revealed that the enclosures containing genetically modified mosquitoes were sealed on August 18. The statement added that “all samples will be destroyed according to an indicated protocol.”
The announcement follows Target Malaria’s second experimental release of 75,000 sterile male GM mosquitoes on August 11 in the village of Souroukoudingan, Karangasso Sambla department, Houet province, and Guiriko region. According to the consortium, the operation aimed to “develop new methods of malaria control” and “strengthen the technical and operational capacity of the research team in managing this type of study.”
The release was conducted in collaboration with the Health Sciences Research Institute/Institute for Research in Health Sciences (IRSS) and supported by the Gates Foundation. Target Malaria said the trial was intended to evaluate the effectiveness of genetically modified mosquitoes as a potential malaria-control tool, in addition to existing measures such as insecticide-treated nets, insecticides, medicines, and vaccines.
This phase built on a smaller trial in July 2019, when 10,000 non-gene drive sterile male mosquitoes, imported as eggs from Italy, were released in Bana, district 7 of Bobo-Dioulasso. In its 2019 “Mark-Release-Capture” report, Target Malaria stated that “at the end of our research programme, if gene drive technology proves reliable, safe, effective, and sustainable, and if it is approved by national regulatory authorities, local communities, and other potentially impacted stakeholders, it will be provided for use in malaria-affected countries through an open access agreement.”
Before this year’s release, the group said it had secured the necessary authorisations, including a “favourable opinion on environmental and social feasibility” from the National Assessment Agency (ANEVE), as well as approvals from the National Biosafety Agency (ANB), the Ethics Committee for Health Research, and the Institutional Ethics Committee of the IRSS.
Despite these regulatory clearances, civil society groups strongly opposed the experiment. The Coalition for Monitoring Biotechnology Activities in Burkina Faso (CVAB) urged authorities to suspend the release and convene expert dialogue, warning that proven alternatives, such as safe and effective anti-malaria drugs, should be prioritised. CVAB member Aly Tapsoba described gene-drive technology as “a poorly understood technology,” stressing that “science has not yet accumulated sufficient experimental data on the inheritance of gene-drives” and warned of potential environmental and health risks.
Critics also pointed to possible conflicts of interest. Burkina Faso’s Health and Public Hygiene Minister, Robert Lucien Kargougou, serves on the board of the Global Alliance for Vaccines and Immunisation (GAVI), a public-private partnership strongly backed by the Gates Foundation and influential in shaping global vaccine markets.
Earlier risk assessments highlighted uncertainties about the approach. In 2014, the Foundation for the National Institutes of Health (FNIH), a Target Malaria funder, commissioned the Commonwealth Scientific and Industrial Research Organisation (CSIRO) to examine the risks of releasing the transgenic male-sterile strain. CSIRO concluded that if sterility persisted when GM mosquitoes bred with wild populations, the modified strain would eventually die out, serving as a controlled step toward malaria eradication. However, if sterility failed, engineered DNA could persist in wild populations, raising unresolved questions about unintended environmental and health consequences.
With the government’s decision, Burkina Faso has become the first country to formally shut down Target Malaria’s activities nationwide, reflecting growing scepticism over the safety, ethics, and necessity of gene-drive mosquito experiments.
——————————————————————————————–
Item 2
PRESS RELEASE
The Coalition for Monitoring Biotechnology Activities (CVAB) welcomes the government’s decision to terminate the “Target Malaria” project.
Ouagadougou, August 22, 2025
The Coalition for Monitoring Biotechnology Activities (CVAB) welcomes with great relief and deep satisfaction the decision of the Government of Burkina Faso to end the Target Malaria project activities throughout the national territory. This wise, responsible, and historic decision marks an important step in preserving the scientific and health sovereignty of our country, Burkina Faso. It also demonstrates the authorities’ willingness to opt for solutions that respect public health, the environment, and citizens’ choices.
The CVAB reaffirms that malaria is a national tragedy, causing grief to thousands of families each year. It hopes that the Burkinabe government will intensify the development and implementation of safe, inclusive, and proven public policies for the eradication of this disease. Several countries have succeeded in being certified malaria-free thanks to reliable and proven methods. Burkina Faso can also meet this challenge with strategies adapted to its realities.
The CVAB expresses its deep gratitude to all those who, directly or indirectly, contributed to ensuring that the voice of civil society was heard in this process.
Done in Ouagadougou, August 22, 2025
For the Coalition for Monitoring Biotechnology Activities (CVAB)
Signed:
- FIAN Burkina Faso;
- Coalition of NGOs and Association for Peasant Seeds (COASP) Burkina;
- Coalition for the Protection of African Genetic Heritage (COPAGEN) Burkina Faso;
- National Council for Organic Agriculture (CNABio);
- Africa Technology Assessment Platform (Afritap);